Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis

Current Oncology

Volumn 18, Issue 6, 2011, Pages 280-284

  Szwajcer, David ^a,b   Czaykowski, P ^a,b   Turner, D ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

Author keywords

Antineoplastic chemotherapy; Emergency department; Febrile neutropenia

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BREAST CANCER; CANCER PATIENT; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; CONTROLLED STUDY; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE UNIT; LARGE CELL LYMPHOMA; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; QUALITY CONTROL; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY HEALTH CARE; THERAPY DELAY;

EID: 82955194539     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i6.841     Document Type: Article

References (19)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (iatcg) of the European Organization for Research and Treatment of Cancer (eortc). Eur J Cancer 1994;30A:430-7.
3. Cordonnier C, Herbrecht R, Buzyn A, et al. Risk factors for gram-negative bacterial infections in febrile neutropenia. Haematologica 2005;90:1102-9.
4. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004;39(suppl 1):S32-7.
5. Nirenberg A, Mulhearn L, Lin S, Larson E. Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 2004;31:711-15.
6. Baltic T, Schlosser E, Bedell MK. Neutropenic fever: one institution's quality improvement project to decrease time from patient arrival to initiation of antibiotic therapy. Clin J Oncol Nurs 2002;6:337-40.
7. Natsch S, Kullberg BJ, van der Meer JW, Meis JF. Delay in administering the first dose of antibiotics in patients admitted to hospital with serious infections. Eur J Clin Microbiol Infect Dis 1998;17:681-4.
8. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
9. Beveridge R. caep issues. The Canadian Triage and Acuity Scale: a new and critical element in health care reform. Canadian Association of Emergency Physicians. J Emerg Med 1998;16:507-11.
10. Cronin G. Balanced Score Card-Child Health Program Winnipeg Regional Health Authority. Winnipeg, MB: Winnipeg Regional Health Authority; September 30, 2006.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
13. Bow EJ, Ramesar K. Guidelines for the Management and Monitoring of Low-Risk Versus High-Risk Febrile Neutropenic Cancer Patients Managed at Cancer Care Manitoba, the Health Sciences Centre, and St. Boniface General Hospital. Winnipeg, MB: Winnipeg Regional Health Authority; 2005.
14. Bradley EH, Herrin J, Elbel B, et al. Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA 2006;296:72-8.
15. Wang TY, Fonarow GC, Hernandez AF, et al. The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. Arch Intern Med 2009;169:1411-19.
16. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With the Guidelines" program. Arch Intern Med 2008;168:411-17.
17. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
18. Sierra J, Szer J, Kassis J, et al. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008;8:195.
19. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.